US2014113290A1PendingUtilityA1
Aberrant methylation of c6orf150 dna sequences in human colorectal cancer
Est. expiryAug 27, 2029(~3.1 yrs left)· nominal 20-yr term from priority
G01N 33/57535G01N 2500/10C12Q 2600/136G01N 2800/56C12Q 2600/154C12Q 1/6886C12Q 2600/156
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This application describes methods and compositions for detecting and treating C6Orf150-associated neoplasia. Differential methylation of the C6Orf150 nucleotide sequences has been observed in C6Orf150-associated neoplasia such as colon neoplasia.
Claims
exact text as granted — not AI-modified1 - 29 . (canceled)
30 . A method for detecting colon cancer, comprising:
a) obtaining a sample from a patient; and b) assaying said sample for the presence of methylation of nucleotide sequences within at least two genes selected from: C6Orf150, SLC5A8, HLTF, p16, and hMLH1; wherein methylation of nucleotide sequences within any of the genes is indicative of colon cancer.
31 . The method of claim 30 , wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.
32 . The method of claim 31 , wherein the bodily fluid is obtained from a subject suspected of having or is known to have colon cancer.
33 - 53 . (canceled)Join the waitlist — get patent alerts
Track US2014113290A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.